Aptevo Therapeutics Inc. (APVO )

Currency in USD Disclaimer
$0.24 +$0.04 (20.35%)
Closed 10/21/2024
$0.21
$0.45
$0.14
$15.31

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol APVO
  • Company Aptevo Therapeutics Inc.
  • Price $0.24
  • Changes Percentage 20.35
  • Change 0.0404
  • Day Low $0.21
  • Day High $0.45
  • Year High $15.31
  • Year Low $0.14
  • Market Cap $2,250,718
  • Price Avg 50 EMA (D) $0.27
  • Price Avg 200 EMA (D) $2.32
  • Exchange NASDAQ
  • Volume 155,039,576
  • Average Volume 1,165,953
  • Open $0.24
  • Previous Close $0.2
  • EPS -35.64
  • PE -0.01
  • Earnings Announcement 2024-11-12 13:30:00
  • Shares Outstanding $9,421,170

Company brief: APTEVO THERAPEUTICS INC. (APVO )

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Corporation News

Income Statement